Background and purpose: Nebivolol is a highly selective β1‐adrenoceptor antagonist with
β3‐adrenoceptor agonist properties and is a racemate mixture of D‐and L‐enantiomers …

Nebivolol, a selective β‐adrenoceptor (β1‐AR) antagonist, induces vasodilatation by an
endothelium‐and NO‐cGMP‐dependent pathway. However, the mechanisms involved in …

Nebivolol is a highly selective β 1 adrenoceptor blocker with additional vasodilating
properties. Although it has been shown that the nebivolol-induced vasorelaxation is nitric …

Nebivolol, a racemic mixture of (S, R, R, R) and (R, S, S, S) enantiomers, is the most β 1-
selective adrenoceptor antagonist currently available for clinical use. However, its …

Nebivolol is a selective β1-adrenoceptor antagonist which, in addition, displays endothelium-
dependent vasodilating properties in humans and other species. β3-Adrenoceptors have …

Nebivolol is a racemic mixture of d‐and 1‐enantiomers. The drug is characterized by β1‐
adrenoceptor selectivity and long‐acting β1‐blockade exerted predominantly by d …

Nebivolol is a highly selective β1-adrenergic receptor antagonist that also possesses
vasodilator properties that are attributed largely to nitric oxide (NO). The objective of the …

There is an ongoing discussion on whether or not high β1-adrenoceptor selectivity of β-
adrenoceptor antagonists may be favorable in the treatment of patients with heart failure …

Nebivolol is a racemic combination of d‐nebivolol (+ SRRR nebivolol) and l‐nebivolol (–
RSSS nebivolol) that differs chemically from other β‐blockers, with an absolutely …

Nebivolol is a new ß,-antagonist that acutely reduces arterial blood pressure without
depressing cardiac function. The present study was designed to determine the effect of …